Education and Training
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
The purpose of this study is to understand physician treatment decisions in selecting specific second line treatments in pediatric ITP and to determine the effectiveness of different second line ITP treatments. Eligible patients are those ages 1-18 years who are starting on a new second line treatment for ITP, defined as any treatment other than IVIG, steroids, anti-D globulin, or aminocaproic acid. Enrolled patients remain on the study for approximately one year.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Second Line ITP agents
Eligibility
Inclusion Criteria:
- Immune Thrombocytopenia or Evans Syndrome
- Ages > 12 months to <18 years
- Starting a new second line therapy as defined as any therapy except IVIG, steroids,
anti-D globulin, or aminocaproic acid
- Starting a single agent/monotherapy
Exclusion Criteria:
- Evans Syndrome with a history of or current evidence of autoimmune hemolytic anemia
- Unwillingness to be followed for 1 year
- Physician providing care is unwilling to participate
- Patient is starting multiple second line agents simultaneously
Ages Eligible for Study
1 Year - 18 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michael Jeng
6507361177
Not Recruiting